missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human GPN1 (aa 213-302) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (92%), Rat (92%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-57822 (PA5-57822. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Small GTPase required for proper nuclear import of RNA polymerase II (RNAPII) (PubMed:20855544, PubMed:21768307). May act at an RNAP assembly step prior to nuclear import (PubMed:21768307). Forms an interface between the RNA polymerase II enzyme and chaperone/scaffolding proteins, suggesting that it is required to connect RNA polymerase II to regulators of protein complex formation (PubMed:17643375). May be involved in nuclear localization of XPA (PubMed:11058119).
Specifications
Specifications
| Accession Number | Q9HCN4 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 11321 |
| Name | Human GPN1 (aa 213-302) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 2410004J02Rik; AI449615; ATP(GTP)-binding protein; ATPBD1A; GPN1; GPN-loop GTPase 1; HUSSY-23; MBD2-interacting protein; MBDIN; methyl-CpG binding domain protein 2 interacting protein; NTPBP; RNA polymerase II associated protein 4; RNAPII-associated protein 4; RPAP4; XAB1; XPA binding protein 1; XPA binding protein 1, GTPase; XPA-binding protein 1 |
| Common Name | GPN1 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction